MXPA02009481A - Factor inductor del factor nuclear kb. - Google Patents

Factor inductor del factor nuclear kb.

Info

Publication number
MXPA02009481A
MXPA02009481A MXPA02009481A MXPA02009481A MXPA02009481A MX PA02009481 A MXPA02009481 A MX PA02009481A MX PA02009481 A MXPA02009481 A MX PA02009481A MX PA02009481 A MXPA02009481 A MX PA02009481A MX PA02009481 A MXPA02009481 A MX PA02009481A
Authority
MX
Mexico
Prior art keywords
nfif
polypeptides
methods
factor
nfkb
Prior art date
Application number
MXPA02009481A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Haws
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0018307.9A external-priority patent/GB0018307D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MXPA02009481A publication Critical patent/MXPA02009481A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA02009481A 2000-03-31 2001-04-02 Factor inductor del factor nuclear kb. MXPA02009481A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19390500P 2000-03-31 2000-03-31
GBGB0018307.9A GB0018307D0 (en) 2000-07-26 2000-07-26 Polypeptides
PCT/US2001/010719 WO2001074900A2 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor

Publications (1)

Publication Number Publication Date
MXPA02009481A true MXPA02009481A (es) 2004-05-14

Family

ID=26244722

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009481A MXPA02009481A (es) 2000-03-31 2001-04-02 Factor inductor del factor nuclear kb.

Country Status (14)

Country Link
EP (1) EP1290023B1 (https=)
JP (1) JP4750999B2 (https=)
KR (1) KR100811571B1 (https=)
AT (1) ATE486089T1 (https=)
AU (1) AU4793101A (https=)
CA (1) CA2404688C (https=)
DE (1) DE60143354D1 (https=)
DK (1) DK1290023T3 (https=)
IL (3) IL151987A0 (https=)
MX (1) MXPA02009481A (https=)
NO (1) NO331972B1 (https=)
NZ (1) NZ521786A (https=)
PT (1) PT1290023E (https=)
WO (1) WO2001074900A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486053T3 (de) 1983-10-20 2004-01-08 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2108144A1 (en) 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
CA2249206A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6132964A (en) * 1998-02-06 2000-10-17 Incyte Pharmaceuticals, Inc. Hydrolase enzymes
EP1105474A2 (en) * 1998-05-14 2001-06-13 Chiron Corporation Human genes and gene expression products v
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6077672A (en) * 1998-08-28 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of TRADD expression
CN1302897A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001251351A1 (en) * 2000-04-05 2001-10-23 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
CA2411601A1 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
EP1290023A2 (en) 2003-03-12
DE60143354D1 (de) 2010-12-09
NZ521786A (en) 2004-07-30
DK1290023T3 (da) 2011-02-14
IL151987A0 (en) 2003-04-10
PT1290023E (pt) 2011-01-05
WO2001074900A3 (en) 2002-05-02
KR20020087459A (ko) 2002-11-22
IL151987A (en) 2010-12-30
CA2404688C (en) 2012-07-31
NO20024656L (no) 2002-11-28
AU4793101A (en) 2001-10-15
HK1053312A1 (en) 2003-10-17
ATE486089T1 (de) 2010-11-15
JP2003529360A (ja) 2003-10-07
WO2001074900A2 (en) 2001-10-11
EP1290023B1 (en) 2010-10-27
WO2001074900A9 (en) 2003-03-06
JP4750999B2 (ja) 2011-08-17
KR100811571B1 (ko) 2008-03-10
CA2404688A1 (en) 2001-10-11
IL198132A0 (en) 2011-08-01
NO331972B1 (no) 2012-05-14
NO20024656D0 (no) 2002-09-27

Similar Documents

Publication Publication Date Title
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
SE9800836D0 (sv) New Compounds
ATE232396T1 (de) Oxydiertes thymosin beta 4
CY1120241T1 (el) Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
EP1446012A4 (en) Bacteriolytic combination therapy for the treatment of tumors
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR200102958T2 (tr) Siklooksijenaz-2 inhibitörleri olarak 4,5-diaril-3(2H)-furanon türevleri.
NO20003288L (no) Preparat for behandling av respiratoriske sykdommer og hudsykdommer, omfattende minst en leukotrienantagonist og minst ett antihistamin
HUP9900819A1 (hu) Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
GB2368064B (en) DNA Element and Associated Protein
AP2000001999A0 (en) Gene therapy method.
MXPA02009481A (es) Factor inductor del factor nuclear kb.
WO2002059327A3 (en) Sulfatases and methods of use thereof
WO2002058681A8 (fr) Utilisation d'une rhéine pour la préparation d'un médicament pour le traitement d'un taux élevé d'il-1.
TR199901385T2 (xx) Piperidin t�revleri.
ITRM990719A0 (it) Uso di ubichinone q10 per il trattamento locale e la prevenzione di patalogie aftalmologiche secondarie alla terapia fotorefrattiva, chirurg
AP2009004857A0 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures,which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
WO1999014322A3 (en) Allelic variant of human stat3
BR0109721A (pt) Fator de indução do fator kb nuclear
ATE340576T1 (de) Wirkstoff-kombination zur medikamentösen therapie der nikotinabhängigkeit
SE9803158D0 (sv) A new composition
Chiu et al. Implementation of Taiwan relations act: An examination after twenty years
ITBO20000360A0 (it) Apparecchiatura di elettrostimolazione del corpo umano .
WO1999037774A3 (en) Differentiation-associated sequences and methods of use therefor

Legal Events

Date Code Title Description
FG Grant or registration